Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

aTYR PHARMA (ATYR) EBITDA (2019 - 2025)

aTYR PHARMA's EBITDA history spans 7 years, with the latest figure at -$14.8 million for Q4 2025.

  • For Q4 2025, EBITDA rose 6.47% year-over-year to -$14.8 million; the TTM value through Dec 2025 reached -$77.6 million, down 14.3%, while the annual FY2025 figure was -$77.6 million, 14.3% down from the prior year.
  • EBITDA reached -$14.8 million in Q4 2025 per ATYR's latest filing, up from -$26.7 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$7.2 million in Q1 2021 to a low of -$26.7 million in Q3 2025.
  • Average EBITDA over 5 years is -$14.0 million, with a median of -$13.5 million recorded in 2022.
  • Peak YoY movement for EBITDA: plummeted 485.64% in 2021, then grew 7.99% in 2022.
  • A 5-year view of EBITDA shows it stood at -$8.6 million in 2021, then grew by 7.99% to -$8.0 million in 2022, then tumbled by 100.74% to -$16.0 million in 2023, then rose by 0.87% to -$15.8 million in 2024, then rose by 6.47% to -$14.8 million in 2025.
  • Per Business Quant, the three most recent readings for ATYR's EBITDA are -$14.8 million (Q4 2025), -$26.7 million (Q3 2025), and -$20.3 million (Q2 2025).